The imaging agent is used to detect estrogen receptor-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. At the moment, the current rate of reimbursement is $0.752 per millicurie for Medicare patients instead of $608.33 per millicurie.

CMS said any corrections would be retroactive to January 1, but the correction isn't likely to happen until March for April or July implementation, according to the SNMMI.